Clinicians need to be informed about the importance of MSI-H/dMMR testing in patients with GI tumors and updated on the most recent clinical evidence to ensure that they select the most appropriate treatment options for their patients.

Anal cancer is rare but increasing in incidence, making education on how to treat advanced or metastatic disease important for clinicians. There have recently been significant, practice-changing developments in systemic therapy options for advanced anal cancer based on clinical trial results and pending FDA approvals, making this a timely topic for discussion.